• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Revvity Inc.

    3/13/24 8:02:57 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    DEFA14A 1 d109956ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒       Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    Revvity, Inc.

    (Name of Registrant as Specified in its Charter)

    Not applicable.

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒   No fee required.
    ☐   Fee paid previously with preliminary materials.
    ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

                    
                         
       

     

    Your Vote Counts!

          

           LOGO

     

    REVVITY, INC.

     

    940 WINTER STREET

    WALTHAM, MA 02451

     

     

    REVVITY, INC.

     

    2024 Annual Meeting

    Vote by April 22, 2024 11:59 PM ET. For shares held in a

    Plan, vote by April 18, 2024 11:59 PM ET.

     

         
       
      LOGO       
       
       
         
         

     

         
     
     
         
     
         

    V31376-P04616-Z86855

                  
               

    You invested in REVVITY, INC. and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on April 23, 2024.

    Get informed before you vote

    View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 9, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

    LOGO

    *Please check the meeting materials for any special requirements for meeting attendance.


    Vote at www.ProxyVote.com

     

     

    THIS IS NOT A VOTABLE BALLOT

    This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

     

     Voting Items  

    Board

    Recommends

     

    1.

     

    To elect ten nominees for director for terms of one year each:

     

    Nominees:

     

       

    1a.

      Peter Barrett, PhD   LOGO   For
     

    1b.

      Samuel R. Chapin   LOGO   For
     

    1c.

      Michael A. Klobuchar   LOGO   For
     

    1d.

      Michelle McMurry-Heath, MD, PhD   LOGO   For
     

    1e.

      Alexis P. Michas   LOGO   For
     

    1f.

      Prahlad R. Singh, PhD   LOGO   For
     

    1g.

      Sophie V. Vandebroek, PhD   LOGO   For
     

    1h.

      Michel Vounatsos   LOGO   For
     

    1i.

      Frank Witney, PhD   LOGO   For
     

    1j.

      Pascale Witz   LOGO   For
     

    2.

      To ratify the selection of Deloitte & Touche LLP as Revvity’s independent registered public accounting firm for the current fiscal year.   LOGO   For
     

    3.

      To approve, by non-binding advisory vote, our executive compensation.   LOGO   For
     

    4.

      To approve the shareholder proposal regarding simple majority voting, if properly presented at the annual meeting.   LOGO   Against

    NOTE: The proxies are authorized to vote, in their discretion, upon such other business as may properly come before the meeting or any adjournment or postponement thereof.

         

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

     

    V31377-P04616-Z86855           

    Get the next $RVTY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    12/15/2025$110.00Buy → Neutral
    BofA Securities
    12/9/2025$105.00Neutral
    Goldman
    10/16/2025Neutral
    Guggenheim
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    More analyst ratings

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

    New launches in high-content imaging, detection, and automation help labs accelerate drug discovery workflows from sample to insight Revvity, Inc. (NYSE:RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation. At booth #612, Revvity will showcase an expanded

    2/5/26 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

    Fourth quarter revenue of $772 million; 6% revenue growth; 4% organic growth Fourth quarter GAAP EPS of $0.87; Adjusted EPS from continuing operations of $1.70 Initiates full year 2026 guidance Revvity, Inc. (NYSE:RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for the same period a year ago.

    2/2/26 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening,

    1/26/26 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Revvity downgraded by BofA Securities with a new price target

    BofA Securities downgraded Revvity from Buy to Neutral and set a new price target of $110.00

    12/15/25 9:57:25 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Goldman initiated coverage on Revvity with a new price target

    Goldman initiated coverage of Revvity with a rating of Neutral and set a new price target of $105.00

    12/9/25 8:53:25 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Guggenheim initiated coverage on Revvity

    Guggenheim initiated coverage of Revvity with a rating of Neutral

    10/16/25 8:27:52 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    SEC Filings

    View All

    Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REVVITY, INC. (0000031791) (Filer)

    2/2/26 7:05:11 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - REVVITY, INC. (0000031791) (Filer)

    1/13/26 9:14:58 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Revvity Inc.

    10-Q - REVVITY, INC. (0000031791) (Filer)

    11/4/25 4:08:31 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Vohra Tajinder S covered exercise/tax liability with 359 shares and was granted 4,448 shares, increasing direct ownership by 39% to 14,531 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    2/6/26 4:05:08 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Singh Prahlad R. covered exercise/tax liability with 3,421 shares, was granted 26,796 shares, exercised 25,525 shares at a strike of $92.09 and sold $2,557,859 worth of shares (25,525 units at $100.21), increasing direct ownership by 24% to 120,213 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    2/6/26 4:05:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Goldberg Joel S covered exercise/tax liability with 869 shares, was granted 6,427 shares, exercised 12,717 shares at a strike of $92.09 and sold $1,274,357 worth of shares (12,717 units at $100.21), increasing direct ownership by 15% to 43,247 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    2/6/26 4:05:06 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:28:28 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Revvity Inc.

    SC 13G - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:22:34 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

    Fourth quarter revenue of $772 million; 6% revenue growth; 4% organic growth Fourth quarter GAAP EPS of $0.87; Adjusted EPS from continuing operations of $1.70 Initiates full year 2026 guidance Revvity, Inc. (NYSE:RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for the same period a year ago.

    2/2/26 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening,

    1/26/26 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

    Revvity, Inc. (NYSE:RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. Update on Financial Performance The Company is also providing the following preliminary financial results for the fourth quarter 2025: Reported and organic revenue growth for the fourth

    1/12/26 4:15:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials